CD8A and neoplasm: Since CD8+ T-cells are the most important mediators of anti-tumor immunity, we used tumor-specific OT-I T-cells (reactive to OVA peptide) to screen GeCKO B16/OVA cells in order to identify candidate genes involved in immune resistance.